683 Capital Management LLC Lowers Stock Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

683 Capital Management LLC lowered its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 41.5% in the fourth quarter, Holdings Channel.com reports. The firm owned 918,117 shares of the company’s stock after selling 652,171 shares during the quarter. 683 Capital Management LLC’s holdings in iTeos Therapeutics were worth $7,051,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in the stock. Virtus ETF Advisers LLC raised its stake in iTeos Therapeutics by 58.2% in the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock valued at $69,000 after purchasing an additional 3,293 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of iTeos Therapeutics during the 3rd quarter valued at about $102,000. Clear Harbor Asset Management LLC purchased a new position in iTeos Therapeutics in the 4th quarter valued at about $96,000. SG Americas Securities LLC grew its position in shares of iTeos Therapeutics by 12.2% during the fourth quarter. SG Americas Securities LLC now owns 13,866 shares of the company’s stock worth $106,000 after buying an additional 1,508 shares in the last quarter. Finally, Marquette Asset Management LLC acquired a new stake in shares of iTeos Therapeutics in the 4th quarter valued at about $122,000. Hedge funds and other institutional investors own 97.16% of the company’s stock.

iTeos Therapeutics Trading Up 3.4 %

Shares of ITOS stock opened at $7.50 on Friday. iTeos Therapeutics, Inc. has a 1 year low of $4.80 and a 1 year high of $18.75. The firm has a market capitalization of $286.46 million, a P/E ratio of -2.38 and a beta of 1.43. The firm’s fifty day simple moving average is $6.57 and its 200 day simple moving average is $7.55.

iTeos Therapeutics (NASDAQ:ITOS) last announced its earnings results on Monday, April 28th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.14. Equities research analysts anticipate that iTeos Therapeutics, Inc. will post -3.49 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on ITOS shares. JPMorgan Chase & Co. cut their target price on shares of iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating on the stock in a report on Thursday, March 6th. Wedbush reiterated an “outperform” rating and set a $25.00 price target on shares of iTeos Therapeutics in a research report on Wednesday, March 5th. HC Wainwright restated a “buy” rating and set a $46.00 target price on shares of iTeos Therapeutics in a report on Thursday, March 6th. Finally, Wells Fargo & Company cut their price target on shares of iTeos Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a report on Tuesday.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.